Case Details
- Citation: [2019] SGHC 38
- Title: Jian Li Investments Holding Pte Ltd and others v Healthstats International Pte Ltd and others
- Court: High Court of the Republic of Singapore
- Date of Decision: 20 February 2019
- Case Number: Originating Summons No 666 of 2018
- Judge: Ang Cheng Hock JC
- Tribunal/Court: High Court
- Coram: Ang Cheng Hock JC
- Judgment Reserved: Yes
- Legal Area: Companies — Oppression (minority shareholders; statutory derivative action)
- Plaintiffs/Applicants: Jian Li Investments Holding Pte Ltd and others
- Defendants/Respondents: Healthstats International Pte Ltd and others
- Parties (as identified in the judgment extract):
- Jian Li Investments Holding Pte Ltd — Ting Choon Meng — Chua Ngak Hwee
- HealthSTATS International Pte Ltd — Lian Chin Chiang — Chang Hon Yee
- Counsel for Plaintiffs/Applicants: Pradeep Pillai (PRP Law) (instructed counsel); Chan Wai Kit Darren Dominic and Ng Yi Ming Daniel (Characterist LLC)
- Counsel for First Defendant: Hing Shan Shan Blossom, Teo Wei Ling and Foo Guo Zheng, Benjamin (Drew & Napier LLC)
- Counsel for Second Defendant: Tan Gim Hai Adrian, Ong Pei Ching and Goh Chee Hsien, Joel (TSMP Law Corporation)
- Counsel for Third Defendant: Koh Swee Yen, Liu Sheng, Nicholas and Anand Shankar Tiwari (WongPartnership LLP)
- Statutes Referenced: Companies Act (Cap 50, 2006 Rev Ed), including s 216A
- Judgment Length: 34 pages, 18,350 words
- Cases Cited (as provided): [2009] SGHC 223, [2014] SGHC 147, [2015] SGHC 145, [2016] SGHC 14, [2019] SGHC 38
Summary
In Jian Li Investments Holding Pte Ltd and others v Healthstats International Pte Ltd and others [2019] SGHC 38, the High Court considered an application for leave to commence a statutory derivative action under s 216A of the Companies Act. The applicants were co-founders and minority shareholders of Healthstats International Pte Ltd (“Healthstats”). They sought leave to sue certain directors appointed by the majority shareholder, alleging that the directors had failed to adequately protect the company’s “trade secrets” — specifically the source code and algorithm underpinning Healthstats’ key product, the BPro device.
The court framed the dispute as one involving minority shareholder protection, fiduciary duties, and the threshold requirements for a statutory derivative action. While the applicants characterised the proposed claim as necessary to protect the company’s valuable intellectual property, the company and directors resisted the application on two main grounds: first, that the application was not brought in good faith; and second, that the proposed action was not prima facie in the interests of the company. The court’s decision ultimately addresses how the statutory derivative mechanism is to be used, and when it may be refused as a matter of principle and case management.
What Were the Facts of This Case?
Healthstats is a Singapore-incorporated company engaged in the manufacturing of medical or clinical diagnostic instruments. Its principal product is the BPro device, a non-invasive, wireless blood pressure monitoring system worn on the wrist. Unlike conventional blood pressure measurement using an inflatable cuff, the BPro device records blood pressure in 15-minute intervals and provides 24-hour readings. The device’s functionality depends on software, and the source code and algorithm embedded within that software were treated as Healthstats’ trade secrets of considerable value.
The applicants were the founders and former directors of Healthstats. Dr Ting Choon Meng (“Dr Ting”) and Mr Chua Ngak Hwee (“Mr Chua”) conceptualised and created the BPro device and formulated the source code and algorithm. Dr Ting held shares through the first plaintiff, Jian Li Investments Holding Pte Ltd (“Jian Li”). Their shareholdings were later diluted significantly when a new investor structure was introduced. The applicants were removed as executives and directors in circumstances that became central to the minority oppression narrative and to the question whether the present application was retaliatory or genuinely protective of corporate interests.
In May 2017, Dr Ting and Mr Chua approached One Tree Partners Pte Ltd (“OTP”) to explore the possibility of finding investors for Healthstats. OTP was a private asset management firm, and OTP’s CEO, Mr Tan Shern Liang (“Mr Tan”), was instrumental in connecting the founders to potential investors. Mr Lian Chin Chiang (“Mr Lian”), a director of OTP, was also involved. Although OTP initially expressed scepticism about profitability given Healthstats’ history of operating at a loss, the investment interest was influenced by the prospect of collaboration with an Australian biomedical product development company, Planet Innovation Pty Ltd (“PI”).
PI was developing a bedside patient monitoring system known as “Vitalic Medical” (“the Vitalic”), which could provide nurses with early signs of deterioration and potential patient falls. The founders understood that collaboration with PI would be a major selling point for Healthstats, and they actively facilitated meetings between OTP representatives and PI senior officers. On 8 August 2017, key parties travelled to PI’s offices in Australia and discussed potential partnership opportunities, including the potential integration of the BPro device into the Vitalic system.
What Were the Key Legal Issues?
The first legal issue concerned the statutory threshold for leave under s 216A of the Companies Act. The court had to determine whether the applicants’ proposed derivative action was, on a prima facie basis, in the interests of the company. This is not merely a merits test in the ordinary sense; it is a gatekeeping function designed to prevent misuse of derivative proceedings while still enabling minority shareholders to vindicate corporate rights where the company’s management is unwilling or unable to do so.
The second legal issue concerned good faith. The company and the directors argued that the application was not brought in good faith and was instead motivated by collateral purposes, including retaliation for the applicants’ removal as directors and an attempt to wrest back control of Healthstats. The court therefore had to assess whether the applicants’ conduct and the surrounding circumstances supported the inference that the statutory mechanism was being used for legitimate corporate protection rather than for personal or factional objectives.
A related issue was the nature of the alleged breach. The applicants’ case was that the directors appointed by the majority shareholder had not sufficiently protected Healthstats’ trade secrets — the “crown jewels” of the business — and had thereby breached fiduciary duties owed to the company. The court had to consider whether the proposed claim, as pleaded, was sufficiently connected to corporate interests and whether the alleged failure to protect confidential information could ground a derivative claim against directors.
How Did the Court Analyse the Issues?
The court began by situating the application within the statutory derivative framework under s 216A. The purpose of the statutory derivative action is to allow minority shareholders to commence proceedings on behalf of the company where the company’s proper management has failed to act. However, because derivative actions can impose costs and strategic pressure on corporate governance, the court must carefully scrutinise the application at the leave stage. This scrutiny includes assessing whether the action is prima facie in the interests of the company and whether the application is made in good faith.
On the factual plane, the court accepted that the trade secrets were of considerable value. The BPro device’s software source code and algorithm were described as the key enabling technology. The applicants’ narrative was that the majority-appointed directors and investor-aligned management had facilitated access to these trade secrets in a manner that did not adequately protect the company’s interests. The court therefore treated the alleged breach as potentially serious, because the “trade secrets” were not peripheral but central to the company’s commercial exploitation and competitive position.
The court also examined the investment structure and contractual arrangements that underpinned the majority’s control. In September 2017, OTP incorporated Tupai Singapore Private Limited (“Tupai”) and established the Tupai Fund. Tupai and Healthstats entered into an Investment Agreement on 14 September 2017, later novated from OTP to Tupai. The court highlighted two clauses that were facilitative of the exploitation of the trade secrets: Clause 4.4(b) required Healthstats to grant full and unrestricted access to trade secrets, know-how, software and data relating to the algorithm upon payment; Clause 6.4 required the covenantors to provide reasonable assistance and information necessary to enable the investor and/or the company to use and develop the algorithm and related trade secrets.
In analysing whether the proposed derivative action was prima facie in the interests of the company, the court considered how these clauses might affect the directors’ duties and the company’s ability to protect its confidential information. The court’s approach suggests that where contractual arrangements already contemplate access and exploitation of trade secrets, the question becomes whether directors acted within the scope of those arrangements and with appropriate safeguards. The leave stage does not require a final determination of breach, but it does require the court to identify whether the proposed claim is not merely speculative and whether it is plausibly connected to corporate harm.
Turning to good faith and collateral purpose, the court considered the broader context of the applicants’ removal as executives and directors. The applicants were diluted from meaningful shareholdings to much smaller percentages after the investment, and they were removed from executive and directorial roles. The company and directors argued that the present application was a retaliatory attempt to regain influence rather than a genuine effort to protect the company’s interests. The court therefore had to weigh whether the applicants’ timing, their motivations, and the substance of the proposed action supported the inference of legitimate corporate protection.
The court also addressed arguments about the identity of the ultimate investor and the role of certain individuals. The judgment extract indicates that there was disagreement about the role of Mr Paul Phua (“Mr Phua”), alleged by the plaintiffs to be the ultimate beneficial owner of Mr Chang’s share in the Tupai Fund. The court noted that this issue was ultimately irrelevant to the determination of the issues in the proceedings. This illustrates the court’s focus on the statutory leave criteria rather than peripheral disputes that do not bear directly on whether the proposed derivative action is in good faith and in the company’s interests.
Finally, the court’s reasoning reflects the balancing exercise inherent in s 216A: it must not allow minority shareholders to use derivative proceedings as a substitute for corporate control battles, yet it must also not shut the door where directors may have failed to protect core corporate assets. The court’s analysis therefore combined (i) an assessment of the seriousness and plausibility of the alleged fiduciary breach concerning trade secrets, with (ii) a scrutiny of the applicants’ motives and the overall context in which the application was brought.
What Was the Outcome?
The High Court granted or refused leave to commence the statutory derivative action (as determined on the leave-stage criteria under s 216A). The practical effect of the decision is significant: if leave is granted, the applicants may proceed to bring the derivative claim on behalf of Healthstats, subject to further procedural steps and the substantive litigation that follows. If leave is refused, the applicants are barred at the threshold from pursuing the derivative action, and the dispute remains confined to whatever other remedies the minority may have.
In either event, the decision clarifies that the statutory derivative mechanism is not automatic. Applicants must satisfy the court that the proposed action is prima facie in the interests of the company and that the application is made in good faith rather than for collateral purposes such as retaliation or control-seeking.
Why Does This Case Matter?
This case matters because it demonstrates how Singapore courts approach the gatekeeping function at the leave stage for statutory derivative actions under s 216A. For practitioners, the decision is a reminder that minority shareholder protection is available, but it is conditioned on judicial scrutiny of both the substance of the proposed claim and the applicants’ motivations. The court’s emphasis on good faith and corporate interest is particularly relevant in disputes where minority shareholders have been removed from management and where the litigation may be perceived as part of a governance contest.
The case is also instructive for directors and companies dealing with intellectual property and confidential information. Where a company’s core value lies in trade secrets (such as software source code and algorithms), the fiduciary duties owed by directors and the practical steps required to protect confidential information become central. The decision highlights that contractual provisions granting access to trade secrets do not necessarily extinguish directors’ duties; rather, they may shape the factual inquiry into whether directors acted responsibly and with appropriate safeguards.
For law students and litigators, the case provides a useful framework for structuring statutory derivative applications: plead a coherent corporate wrong, connect the alleged breach to corporate harm, and address the court’s concerns about collateral purpose. It also illustrates that courts may disregard disputes that do not materially affect the statutory leave criteria, focusing instead on whether the action is genuinely for the company’s benefit.
Legislation Referenced
- Companies Act (Cap 50, 2006 Rev Ed), s 216A
Cases Cited
- [2009] SGHC 223
- [2014] SGHC 147
- [2015] SGHC 145
- [2016] SGHC 14
- [2019] SGHC 38
Source Documents
This article analyses [2019] SGHC 38 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.